Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Hampshire for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Hampshire only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Hampshire (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yoko Fukuda (NPI 1568622801)

Field	Value
Entity Type	Individual
Organization	Yoko Fukuda
Address	155 Borthwick Ave Ste C
City	Portsmouth
State	NH
ZIP	03801
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 10, 2008

Payer Source	Total Paid
Medicare	$945K
Medicaid	$0

Key Findings

YOKO FUKUDA is a Hematology & Oncology physician in PORTSMOUTH, NH with total Medicare revenue of $945K and no Medicaid billing on file, making the provider effectively single‑payer (Medicare) in this dataset. The absence of Medicaid activity suggests payer concentration risk and reliance on Medicare-driven volumes for practice revenue.

Revenue concentration is high: the precomputed top‑3 Medicare codes account for 72.7% of this provider's total Medicare revenue. Those top codes are J9271 ($447.2K, 47.6% of Medicare revenue), J0897 ($157.7K, 16.8%), and J1439 ($77.3K, 8.2%), indicating a small set of drugs strongly dominate income.

The code mix points to an infusion‑centric oncology practice focused on high‑cost biologic/immunotherapy and supportive infusions: J9271 (pembrolizumab), J0897 (denosumab), and J1439 (ferric carboxymaltose) are the primary revenue drivers, and chemotherapy/infusion administration codes such as 96413 ($33.3K, 3.5%) and 96365 ($17K, 1.8%) are also billed. This pattern is consistent with an outpatient oncology infusion operation that pairs cancer immunotherapy with bone‑modifying agents and IV iron.

Competitive standing is mixed across the top medications: J9271 ranks #1128 of 1841 providers nationally (38th percentile), indicating modest national volume for pembrolizumab relative to peers, while J0897 ranks #1388 of 10057 (86th percentile) and J1439 ranks #107 of 1209 (91th percentile) which suggest relatively strong, above‑typical volumes for denosumab and ferric carboxymaltose. In short, the provider is not a dominant national pembrolizumab prescriber but is comparatively high‑volume for certain supportive and infusion drugs.

Visit and intensity metrics show above‑typical E/M activity: 99214 (742 claims, $72.7K, 95th percentile) and 99215 (308 claims, $43.1K, 96th percentile) are both noted as "notably above typical national volume," implying substantial follow‑up and high‑complexity outpatient management accompanying infusion services. This mix indicates the practice manages complex oncology patients and bills proportionately more high‑level office visits than most peers.

Several infusion‑support and device codes are statistical outliers or notably elevated: 96360 (371 claims, $9.6K) is labeled an "extreme outlier, far above typical national volume" (99th percentile) and 96523 (180 claims, $3.6K) ranks in the 98th percentile as "notably above typical national volume." These signals point to high throughput of IV access care, catheter maintenance, and infusion sessions consistent with a busy infusion clinic.

The explicit absence of Medicaid billing ("none below — this provider has no Medicaid billing on file") reinforces that this provider's commercial footprint in public programs is concentrated on Medicare, which may affect network negotiation strategy and vulnerability to Medicare reimbursement changes. Analysts should treat Medicaid exposure as effectively zero in this record.

This NPI has been enumerated since 2008-06-10 (~18 years ago), indicating long tenure in the Medicare program. Combined with $945K lifetime Medicare revenue and the concentrated drug mix, the data portray an established, mid‑scale oncology infusion practice with specialized revenue drivers and limited Medicaid participation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,400	$40	$447.2K
J0897	Injection, denosumab, 1 mg	8,760	$20	$157.7K
J1439	Injection, ferric carboxymaltose, 1 mg	77,250	$1	$77.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	740	$100	$72.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	310	$140	$43.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	310	$110	$33.3K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	60	$340	$20.2K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	320	$50	$17K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	50	$220	$10.8K
96360	The provider introduces a catheter intravenously for supplementation of fluid and electrolytes for 31 minutes to one hour to treat severe cases of dehydration.	370	$30	$9.6K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Hampshire Distribution

Yoko Fukuda — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Hampshire

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	10	10,000	$40	$440.2K
J0897	3	20	2,760	$20	$75.4K
J1439	1	10	77,250	$1	$67.5K
J1454	1	10	60	$330	$18.1K
96413	3	20	140	$100	$15.8K
99214	71	3,150	110	$80	$13.2K
G0498	3	10	50	$220	$10.6K
99223	452	700	30	$130	$7.2K
99213	1,716	2,900	70	$50	$6.9K
99215	16	1,080	40	$110	$6.8K

Showing 1–10 of 41

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yoko Fukuda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Hospital	ME	General Acute Care Hospital	$0	$35.5M
Can Ilyas	ME	Hematology & Oncology Physician	$3.2M	$0
David Benton	ME	Hematology & Oncology Physician	$2.6M	$0
Matthew Dugan	ME	Hematology & Oncology Physician	$1.8M	$0
John Winters	ME	Hematology & Oncology Physician	$1.5M	$0
Maine Center For Cancer Medicine & Blood Disorders, P.A.	ME	Hematology & Oncology Physician	$0	$1.5M
Christian Thomas	ME	Hematology & Oncology Physician	$1.5M	$0
Devon Evans	ME	Hematology & Oncology Physician	$1.5M	$0
Brian Haney	ME	Hematology & Oncology Physician	$1.2M	$0
Jonathan Proulx	NH	Hematology (Internal Medicine) Physician	$725.4K	$0

Nearby Providers

Other providers in the same ZIP code as Yoko Fukuda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Region Viii, One Sky Community Services Inc.	NH	Case Management Agency	$0	$192.2M
Novocure Inc.	NH	Durable Medical Equipment & Medical Supplies	$0	$113.1M
Seacoast Mental Health Center, Inc.	NH	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$74.2M
Hca Health Services Of New Hampshire Inc	NH	General Acute Care Hospital	$0	$18.8M
Pmc Medical Group, LLC	NH	General Practice Physician	$392K	$11.2M
Greater Seacoast Community Health	NH	Federally Qualified Health Center (FQHC)	$0	$6.6M
Kinley Beck	NH	Retina Specialist (Ophthalmology) Physician	$4.2M	$0
Portsmouth School Department	NH	Local Education Agency (LEA)	$0	$2.6M
Preferred Home Health Care And Nursing Services	NH	Durable Medical Equipment & Medical Supplies	$0	$2.3M
Watterworth Orthodontics, PA	NH	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$2.3M

Yoko Fukuda — Billing Profile & Reimbursement Data

Sign up for Yoko Fukuda — Billing Profile & Reimbursement Data policy alerts

Yoko Fukuda — Billing Profile & Reimbursement Data

Sign up for Yoko Fukuda — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References